Acorda reports wider loss, but revenues gain
- November
- 4
Acorda Therapeutics Inc., the Hawthorne company that sells a drug for people with multiple sclerosis, said this morning its third-quarter loss more than doubled to $18.9 million from $8.5 million last year.
On a per-share basis, the company lost 53 cents in the quarter that ended in September, compared with 30 cents last year.
Acorda, which markets the drug Zanaflex, said sales rose to $12.44 million from $10.44 million.
But the company pumped more money into its research and development efforts, spending $8.7 million, compared with $5.6 million last year. The company said the research and development expenses were related to its bid to market Fampridine-SR, a drug to help people with multiple sclerosis walk.
“We made significant progress this quarter in preparing a new drug application for Fampridine-SR, which we expect to submit electronically to the U.S. Food and Drug Administration in the first quarter of 2009,†Dr. Ron Cohen, the company’s president and chief executive, said in a statement released by the company. “We also concluded a series of meetings with four European regulatory agencies, and as a result are planning to file a marketing authorization application for Fampridine-SR in Europe in 2009.â€
Acorda shares were at $21.79 in the early minutes of trading this morning, up 37 cents. On the year, the shares are down by less than 1 percent.









